Based on its negative regulatory effect on secreted phosphoprotein 1 (SPP1) and ERK signals, miR-27a mimics are potential therapeutic agents for counteracting pathological fibrosis and delaying the progression of SSc [133,137]. Here, SPP1 is linked to systemic sclerosis.